Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 91 of 91 entries
View as:

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05039944 Org: User:
Start: 11/30/21 End: 06/06/22 Due: 06/06/23

A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06830889 Org: User:
Start: 06/09/25 End: 12/31/31 Due: 12/31/32

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06755242 Org: User:
Start: 01/31/25 End: 12/31/27 Due: 12/31/28

A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT06857214 Org: User:
Start: 06/04/25 End: 12/31/27 Due: 12/31/28

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06118333 Org: User:
Start: 12/04/23 End: 12/31/25 Due: 12/31/26

Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05623982 Org: User:
Start: 09/26/22 End: 12/31/25 Due: 12/31/26

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT05192486 Org: User:
Start: 08/10/22 End: 12/31/25 Due: 12/31/26

A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06986785 Org: User:
Start: 06/30/25 End: 12/31/27 Due: 12/31/28

A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06668961 Org: User:
Start: 11/07/24 End: 11/30/26 Due: 11/30/27

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04603287 Org: User:
Start: 04/17/20 End: 06/30/25 Due: 06/30/26

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05385692 Org: User:
Start: 06/01/22 End: 06/30/25 Due: 06/30/26

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04794972 Org: User:
Start: 04/14/21 End: 06/30/25 Due: 06/30/26

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06609187 Org: User:
Start: 10/30/24 End: 10/31/26 Due: 10/31/27

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04606433 Org: User:
Start: 11/04/20 End: 11/30/25 Due: 11/30/26

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Phase: N/A Priority: Normal
NCT ID: NCT05627856 Org: User:
Start: 02/21/23 End: 12/31/25 Due: 12/31/26

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06994195 Org: User:
Start: 05/31/25 End: 12/31/27 Due: 12/31/28